Novel Self-assembling Agent, AC5-G™, for Use in Submucosal Lifting in Endoscopic Resection and Management of Gastrointestinal Bleeding

View Video

Demonstration of AC5® Topical Gel in Porcine Full-Thickness Surgical Wound Models

View Wound Care Demonstration Video

LD Micro Main Event

Recent Webcast

Innovative Technology

Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue.

About Arch Therapeutics

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2

1. AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2. AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.


Learn more about Arch Therapeutics and
 its leadership team, poised to meet the challenges of applying innovative biotechnology to develop advanced interventional wound care products.

Learn More


The wound care market seeks products that work better, faster, & more reliably. See how Arch Therapeutics’ platform can address those needs.

Learn More


Find out more about Arch Therapeutics’ product candidates.

Learn More


Find Arch Therapeutics’ recent presentations and more.

Learn More